Cancer Care

 

 
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Principal Investigator (?)
Manno, Phillip
Study Number
NSABP-B43M
Summary
This randomized phase III trial is studying radiation therapy to see how well it works
compared with or without trastuzumab in treating women with ductal carcinoma in situ who
have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Radiation
therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation
therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon
Manchester
Southwestern Vermont

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.